Makhteshim Agan Industries Ltd. and Yissum Technology Transfer Company of the Hebrew University of Jerusalem will jointly develop and commercialize a novel, non-toxic, and environmentally-friendly bio-control method for protecting a variety of plants, based on a naturally-occurring yeast, Pseudozyma that was isolated from strawberry leaves.
HU Biodesign Innovation Program benefits from the expertise of Jerusalem’s best and brightest in medicine, business, engineering and law.
Yissum's spin off Regenecure presents: BoneCure, a revolutionary artificial membrane that speeds and simplifies bone re-growth in pets, may also be headed for the human market.
Yissum spin off Briefcam featured in Mashable: "Using tech to augment how we watch for and catch terrorists and others who would do us harm before they board an aircraft is a process flush with options — and with challenges"
Prof. Yossi Paltiel and research student Oren Ben-Dor at the Hebrew University of Jerusalem's Harvey M. Krueger Family Center for Nanoscience and Nanotechnology, together with researchers from the Weizmann Institute of Science, have developed a simple magnetization progress that, by eliminating the need for permanent magnets in memory devices, opens the door to many technological applications.
The technology transfer companies of the Hebrew University (Yissum) and the Weizmann Institute of Science (Yeda) are working to promote the realization of this technology, by licensing its use and raising funds for further development and commercialization.
Students in Hebrew University-Hadassah Medical Center program develop "science fiction gadgets".
Biodesign entrepreneurship program is Israel's first medical innovation accelerator
Diabetics must be regularly examined by their ophthalmologist to look for leakage of blood inside the retinas of their eyes, which could result in blindness.
Now the Hebrew University of Jerusalem’s technology transfer arm, Yissum Research Development Company, has patented a method for detecting retinal microaneurysms that pose a high risk for leakage. The novel method will enable early diagnosis and treatment of the condition, potentially minimizing damage and saving vision.
Yissum presents exciting technologies at Biomed 2013
This is the largest ever fund raising round by the company, which develops camera-based advanced driver assistance systems for the automotive industry.
Yaacov Michlin, Yissum CEO says: "The key to success for biotech in Israel is starting a small company, then catching the attention of Big Pharma.
Hebrew University is preparing to establish a center for pharmaceutical research and treatment of children, the dean of HU’s School of Pharmacy, Prof.Simon Benita announced on Monday. Half-a-million dollars have already been collected towards establishing the center in the pharmacy school’s Jerusalem Ein Kerem campus.
"The sucess of the Israeli Technology Transfer companies in commercializing academic innovation is key element in Israeli's economy", says Wonjae Lee, head of the Korean office at Yozman Group.
Yissum Spin Off PlantArray places sensors on plants to monitor hundreds of them simultaniously.
Surveillance cameras were not enough to catch the Boston Marathon terrorists. The Israeli-based BriefCam firm “collapsed” an hour of video and focused on suspicious objects – and people. Briefcam, a Yissum spin-off company is a world success.
Prof. Yechezkel Barenholz, co-inventor of the Doxil drug talks of the long journey from lab to market and of his new "baby" start up- Lipocure.
Prof. Marta Weinstock-Rosin was born on the wrong side of a lot of settings: In Austria she was too Jewish, at the British Academy in the early '50s she was too much of a woman, in Israel she was considered too British and for Novartis, manufacturer of her blockbuster drug Exelon she was too Israeli.
Prof. Haim Rabinowitch tell Globes how his scientific research changed the balance of power in agricultural world markets
Investment to Support BriefCam's Global Marketing and Sales Expansion for Video Synopsis Technology
In parallel, Holmen, a leading manufacturer in the forest based sector, has entered into an investment and sub-licensing agreement with Melodea, by which Holmen has become one of the major shareholders in Melodea.